Péc M, Visnovský P, Dobrota D, Dobiás J, Lazár J
Ustav farmakológie Jeseniovej lekárskej fakulty Univerzity Komenského v Martine, Slovakia.
Bratisl Lek Listy. 1993 Sep;94(9):507-9.
The work reviews knowledge about the function of PAF, the presupposed mediator of asthma. The PAF mediator evokes contraction of smooth muscles of respiratory passages, too in vivo as in vitro, by means of an indirect mechanism involving activated platelets which function as intermediaries. The constrictor released due to this process can be represented by histamine or a product of arachidonic acid. Mucous secretion is according to current knowledge stimulated by PAF. The PAF mediator appears to be a considerable chemotactic factor for eosinophils which by their cytotoxic effects on respiratory epithelium support the origin and development of bronchial hyperresponsiveness. PAF has an eminent effect on the growth of microvascular permeability. Antagonists of PAF inhibit some mentioned PAF effects. Their possible therapeutic utilization, excluding ketotiphen, are currently subjected to research. (Fig. 2, Ref. 17.).
这项工作回顾了有关血小板活化因子(PAF)功能的知识,PAF被认为是哮喘的介质。PAF介质通过涉及作为中介的活化血小板的间接机制,在体内和体外均可引起呼吸道平滑肌收缩。由于这一过程释放的收缩剂可以是组胺或花生四烯酸的产物。根据目前的知识,PAF可刺激粘液分泌。PAF介质似乎是嗜酸性粒细胞的重要趋化因子,嗜酸性粒细胞对呼吸道上皮的细胞毒性作用支持支气管高反应性的发生和发展。PAF对微血管通透性的增加有显著作用。PAF拮抗剂可抑制上述一些PAF的作用。目前正在研究它们(不包括酮替芬)可能的治疗用途。(图2,参考文献17)